| Summary: | Introduction: the diabetic foot syndrome is one of the chronic complications of increased morbidity and disability in diabetic patients today. High rates of amputations cause a significant degree of disability with high economic and social cost. It has been shown that administration of Heberprot- P stimulates the formation of granulation tissue in the ulcer bed and closed by second intention .
Objective: to describe the results of treatment with Heberprot -P in patients with a diagnosis of diabetic foot.
Material and methods: a prospective study of 86 patients with diagnosis of diabetic foot in the period January 2010 to December 2013 at the Policlinic "Juan Contreras B. Fowler" in Ranchuelo Municipality, in the Province of Villa Clara, which were applied to the epidermal growth factor intralesionally . Patients taking into account age, sex, personal medical history, the severity depending on the classification of Wagner , the dose and the number of applications, the assessment of response and adverse effects were studied.
Results: in the studied series predominated patients aged between 50 and 59 years old ( 26.74 %), females ( 52.33 %) and diabetes type 2; the number of applications was increased in the plantar ulcer grade III ; full granulation was achieved in 70 % of cases and partial in 24.4%; there was major amputation in two patients with adverse effects and they presented pain and burning.
Conclusions: with the implementation of Heberprot -P has been achieved a favorable outcome in most cases and iit s able to maintain the integrity of the member and its functionality in most patients.
|
|---|